NS Pharma, a subsidiary of Nippon Shinyaku Co., announced that acceptance has been received by Capricor Therapeutics (CAPR) from the U.S. FDA for the Biologics License Application filing for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy cardiomyopathy. The FDA granted the BLA Priority Review with a Prescription Drug User Fee Act target action date of August 31, 2025, and at this time, the FDA has not identified any potential review issues.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Biotech Alert: Searches spiking for these stocks today
- Capricor Therapeutics call volume above normal and directionally bullish
- Capricor Therapeutics options imply 7.5% move in share price post-earnings
- Target reports Q4 beat, Walgreens reportedly near go-private deal: Morning Buzz
- Capricor Therapeutics: Promising Developments and Strategic Positioning Drive Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue